in vitro and ex vivo

In vitro/ex vivo
assays

Obesity Diabetes

Obesity
Diabetes

NASH Fibrosis

NASH / MASH / MetALD
Fibrosis

Diabetic
Nephropathy/CKD

fibrosis

Fibrosis

Diabetic neuropathy

Diabetic
Neuropathy

Immuno metabolism

Immuno
Metabolism

Dyslipidaemia
Atherosclerosis

Nutraceuticals

Nutraceuticals

Consulting

Consulting

PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS

Physiogenex provides preclinical in vivo and ex vivo CRO services with 20 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH/MASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.

We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.

Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.

STATE OF THE ART CRO FACILITIES

Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.

Learn more

High success rate customer satisfaction in 2023: 97.5%

When is your turn?

Indian Pharma customer

“High level of expertise and timely discussions during the study plan and execution Very co-operative”

European Biotech customer

« Great working with Physiogenex: great competence in the area, straight answer and very good team available to support all our needs »

South American Pharma customer

“Once again, I would like to appreciate for all your assistance during the study execution and all technical issues that Physiogenex experts helped us to understand. Physiogenex is a very strategic partner and in the future, we certainly will consider you to perform our preclinical studies.”

US Biotech customer

“Excellent scientific advice provided for the study design. Studies tailored for small biotechs with limited budget. Timelines met, rigor in execution. Indeed, a great partner for drug development in the metabolic disease area.”

US Pharma customer

“I can’t thank you enough for all your great work and support! It was really nice collaborating with you all and I am very much looking forward to the next collaboration with you!”

Korean Pharma customer

“We really appreciate what you did for our study. A new assay development was successful. The study report was well-documented.”

THEY TRUST US

We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies

LATEST NEWS ABOUT PHYSIOGENEX